These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 24269216)

  • 1. Novel GPR40 agonist AS2575959 exhibits glucose metabolism improvement and synergistic effect with sitagliptin on insulin and incretin secretion.
    Tanaka H; Yoshida S; Minoura H; Negoro K; Shimaya A; Shimokawa T; Shibasaki M
    Life Sci; 2014 Jan; 94(2):115-21. PubMed ID: 24269216
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Physiological and pharmacological mechanisms through which the DPP-4 inhibitor sitagliptin regulates glycemia in mice.
    Waget A; Cabou C; Masseboeuf M; Cattan P; Armanet M; Karaca M; Castel J; Garret C; Payros G; Maida A; Sulpice T; Holst JJ; Drucker DJ; Magnan C; Burcelin R
    Endocrinology; 2011 Aug; 152(8):3018-29. PubMed ID: 21673098
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of DPP-4 with sitagliptin improves glycemic control and restores islet cell mass and function in a rodent model of type 2 diabetes.
    Mu J; Petrov A; Eiermann GJ; Woods J; Zhou YP; Li Z; Zycband E; Feng Y; Zhu L; Roy RS; Howard AD; Li C; Thornberry NA; Zhang BB
    Eur J Pharmacol; 2009 Nov; 623(1-3):148-54. PubMed ID: 19765579
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Defining the role of GLP-1 in the enteroinsulinar axis in type 2 diabetes using DPP-4 inhibition and GLP-1 receptor blockade.
    Aulinger BA; Bedorf A; Kutscherauer G; de Heer J; Holst JJ; Göke B; Schirra J
    Diabetes; 2014 Mar; 63(3):1079-92. PubMed ID: 24296715
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential importance of glucose-dependent insulinotropic polypeptide vs glucagon-like peptide 1 receptor signaling for beta cell survival in mice.
    Maida A; Hansotia T; Longuet C; Seino Y; Drucker DJ
    Gastroenterology; 2009 Dec; 137(6):2146-57. PubMed ID: 19766644
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potentiation of insulin secretion and improvement of glucose intolerance by combining a novel G protein-coupled receptor 40 agonist DS-1558 with glucagon-like peptide-1 receptor agonists.
    Nakashima R; Yano T; Ogawa J; Tanaka N; Toda N; Yoshida M; Takano R; Inoue M; Honda T; Kume S; Matsumoto K
    Eur J Pharmacol; 2014 Aug; 737():194-201. PubMed ID: 24858371
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chronic treatment with novel GPR40 agonists improve whole-body glucose metabolism based on the glucose-dependent insulin secretion.
    Tanaka H; Yoshida S; Oshima H; Minoura H; Negoro K; Yamazaki T; Sakuda S; Iwasaki F; Matsui T; Shibasaki M
    J Pharmacol Exp Ther; 2013 Sep; 346(3):443-52. PubMed ID: 23853170
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of long-term dipeptidyl peptidase-IV inhibition on body composition and glucose tolerance in high fat diet-fed mice.
    Liu X; Harada N; Yamane S; Kitajima L; Uchida S; Hamasaki A; Mukai E; Toyoda K; Yamada C; Yamada Y; Seino Y; Inagaki N
    Life Sci; 2009 Jun; 84(25-26):876-81. PubMed ID: 19358859
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes.
    Herman GA; Bergman A; Stevens C; Kotey P; Yi B; Zhao P; Dietrich B; Golor G; Schrodter A; Keymeulen B; Lasseter KC; Kipnes MS; Snyder K; Hilliard D; Tanen M; Cilissen C; De Smet M; de Lepeleire I; Van Dyck K; Wang AQ; Zeng W; Davies MJ; Tanaka W; Holst JJ; Deacon CF; Gottesdiener KM; Wagner JA
    J Clin Endocrinol Metab; 2006 Nov; 91(11):4612-9. PubMed ID: 16912128
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acute dipeptidyl peptidase-4 inhibition rapidly enhances insulin-mediated suppression of endogenous glucose production in mice.
    Duez H; Smith AC; Xiao C; Giacca A; Szeto L; Drucker DJ; Lewis GF
    Endocrinology; 2009 Jan; 150(1):56-62. PubMed ID: 18801896
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of the incretin pathway in the pathogenesis of type 2 diabetes mellitus.
    Freeman JS
    Cleve Clin J Med; 2009 Dec; 76 Suppl 5():S12-9. PubMed ID: 19952298
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Twelve weeks treatment with the DPP-4 inhibitor, sitagliptin, prevents degradation of peptide YY and improves glucose and non-glucose induced insulin secretion in patients with type 2 diabetes mellitus.
    Aaboe K; Knop FK; Vilsbøll T; Deacon CF; Holst JJ; Madsbad S; Krarup T
    Diabetes Obes Metab; 2010 Apr; 12(4):323-33. PubMed ID: 20380653
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DPP4 inhibitors: a new approach in diabetes treatment.
    Doupis J; Veves A
    Adv Ther; 2008 Jul; 25(7):627-43. PubMed ID: 18641927
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Positive interplay between FFAR4/GPR120, DPP-IV inhibition and GLP-1 in beta cell proliferation and glucose homeostasis in obese high fat fed mice.
    Owolabi AI; Corbett RC; Flatt PR; McKillop AM
    Peptides; 2024 Jul; 177():171218. PubMed ID: 38621590
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Restoration of the insulinotropic effect of glucose-dependent insulinotropic polypeptide contributes to the antidiabetic effect of dipeptidyl peptidase-4 inhibitors.
    Aaboe K; Akram S; Deacon CF; Holst JJ; Madsbad S; Krarup T
    Diabetes Obes Metab; 2015 Jan; 17(1):74-81. PubMed ID: 25243647
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of dipeptidyl peptidase-IV activity by metformin enhances the antidiabetic effects of glucagon-like peptide-1.
    Green BD; Irwin N; Duffy NA; Gault VA; O'harte FP; Flatt PR
    Eur J Pharmacol; 2006 Oct; 547(1-3):192-9. PubMed ID: 16945366
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stimulating β-cell regeneration by combining a GPR119 agonist with a DPP-IV inhibitor.
    Ansarullah ; Lu Y; Holstein M; DeRuyter B; Rabinovitch A; Guo Z
    PLoS One; 2013; 8(1):e53345. PubMed ID: 23382843
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sitagliptin reduces hyperglycemia and increases satiety hormone secretion more effectively when used with a novel polysaccharide in obese Zucker rats.
    Reimer RA; Grover GJ; Koetzner L; Gahler RJ; Juneja P; Lyon MR; Wood S
    J Nutr; 2012 Oct; 142(10):1812-20. PubMed ID: 22915295
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A pilot study of the efficacy of miglitol and sitagliptin for type 2 diabetes with a continuous glucose monitoring system and incretin-related markers.
    Kishimoto M; Noda M
    Cardiovasc Diabetol; 2011 Dec; 10():115. PubMed ID: 22189184
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Yhhu4488, a novel GPR40 agonist, promotes GLP-1 secretion and exerts anti-diabetic effect in rodent models.
    Guo DY; Li DW; Ning MM; Dang XY; Zhang LN; Zeng LM; Hu YH; Leng Y
    Biochem Biophys Res Commun; 2015 Oct; 466(4):740-7. PubMed ID: 26417688
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.